These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30460201)

  • 1. Corrigendum: Microenvironment Cell Contribution to Lymphoma Immunity.
    Kumar D; Xu ML
    Front Oncol; 2018; 8():522. PubMed ID: 30460201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment Cell Contribution to Lymphoma Immunity.
    Kumar D; Xu ML
    Front Oncol; 2018; 8():288. PubMed ID: 30101129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum: CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
    Song Y; Song W; Li Z; Song W; Wen Y; Li J; Xia Q; Zhang M
    Front Oncol; 2020; 10():583698. PubMed ID: 33585203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Editorial: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy.
    Valvo VM; Vitale E; Tigano M; Evans R; Morgan MA; Zhang Q
    Front Oncol; 2024; 14():1424895. PubMed ID: 38939331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
    Cao H; Li W; Zhou Y; Tan R; Yang Y; Zhou Y; Guo Q; Zhao L
    Front Oncol; 2019; 9():990. PubMed ID: 31608242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum: Single-cell transcriptomics reveals the complexity of the tumor microenvironment of treatment-naive osteosarcoma.
    Liu Y; Feng W; Dai Y; Bao M; Yuan Z; He M; Qin Z; Liao S; He J; Huang Q; Yu Z; Zeng Y; Guo B; Huang R; Yang R; Jiang Y; Liao J; Xiao Z; Zhan X; Lin C; Xu J; Ye Y; Ma J; Wei Q; Mo Z
    Front Oncol; 2022; 12():1077067. PubMed ID: 36457508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Single-cell technologies to decipher the immune microenvironment in myeloid neoplasms: Perspectives and opportunities.
    Caprioli C; Nazari I; Milovanovic S; Pelicci PG
    Front Oncol; 2022; 12():974476. PubMed ID: 36046050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: Identification of Mitochondrial-Related Prognostic Biomarkers Associated With Primary Bile Acid Biosynthesis and Tumor Microenvironment of Hepatocellular Carcinoma.
    Zhang T; Nie Y; Gu J; Cai K; Chen X; Li H; Wang J
    Front Oncol; 2021; 11():843623. PubMed ID: 35111689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum: Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis.
    Zhuang Z; Zhang Y; Zhang X; Zhang M; Zou D; Zhang L; Jia C; Zhang W
    Front Oncol; 2022; 12():1104236. PubMed ID: 36776380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum: TFEB Promotes Prostate Cancer Progression
    Zhu X; Zhuo Y; Wu S; Chen Y; Ye J; Deng Y; Feng Y; Liu R; Cai S; Zou Z; Wang B; Wu CL; Zeng G; Zhong W
    Front Oncol; 2021; 11():750277. PubMed ID: 34527597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum: C-reactive protein is an indicator of the immunosuppressive microenvironment fostered by myeloid cells in hepatocellular carcinoma.
    Wang Y; Li Z; Huang Z; Yu X; Zheng L; Xu J
    Front Oncol; 2023; 13():1280727. PubMed ID: 37941560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: The epithelial to mesenchymal transition related gene calumenin is an adverse prognostic factor of bladder cancer correlated with tumor microenvironment remodeling, gene mutation, and ferroptosis.
    Du Y; Miao W; Jiang X; Cao J; Wang B; Wang Y; Yu J; Wang X; Liu H
    Front Oncol; 2023; 13():1185029. PubMed ID: 37251925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: The role of NR4A1 in the pathophysiology of osteosarcoma: A comprehensive bioinformatics analysis of the single-cell RNA sequencing dataset.
    Liu W; Hao Y; Tian X; Jiang J; Qiu Q
    Front Oncol; 2022; 12():1027056. PubMed ID: 36176386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: The research progress on radiation resistance of cervical cancer.
    Liang M; Sheng L; Ke Y; Wu Z
    Front Oncol; 2024; 14():1430862. PubMed ID: 38826781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Antitumor effect and immune response of nanosecond pulsed electric fields in pancreatic cancer.
    Zhao J; Chen S; Zhu L; Zhang L; Liu J; Xu D; Tian G; Jiang T
    Front Oncol; 2022; 12():1052763. PubMed ID: 36303831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Effects of alkalization therapy on hepatocellular carcinoma: a retrospective study.
    Isowa M; Hamaguchi R; Narui R; Morikawa H; Wada H
    Front Oncol; 2023; 13():1291026. PubMed ID: 37799473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience.
    Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NSM; Chua DTT; Lee SWM; Chen JS; Yeh CN
    Front Oncol; 2022; 12():1028118. PubMed ID: 36313668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: PET/Ct Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients.
    Rong X; Lv J; Liu Y; Wang Z; Zeng D; Li Y; Li S; Wu J; Shen Z; Shi M; Liao W; Wu Z; Wang C
    Front Oncol; 2022; 12():895938. PubMed ID: 35463347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma.
    Bao J; Xu C; Li B; Wu Z; Shen J; Song P; Peng Q; Hu G
    Front Oncol; 2023; 13():1282120. PubMed ID: 37766865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: Comparison of prognosis between microscopically positive and negative surgical margins for primary gastrointestinal stromal tumors: A systematic review and meta-analysis.
    Liu Z; Zhang Y; Yin H; Geng X; Li S; Zhao J; Zeng Z; Ye X; Yu J; Feng F; Kang W
    Front Oncol; 2022; 12():1110168. PubMed ID: 36761432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.